Tacrolimus as first-line therapy in a US cohort of idiopathic inflammatory myopathies related interstitial lung disease
Authors' conclusion
TAC is effective as a first-line agent in a small, non-randomized US cohort of IIM-ILD enriched for MDA5+ participants.
Study context
- Population
- US cohort of IIM-ILD participants naïve to immunosuppressive agents other than GC and/or intravenous immunoglobulin
- Participants
- 31 participants
- Exposure
- Tacrolimus vs mycophenolate mofetil (MMF)/AZA as first-line immunosuppressive therapy
- Outcome
- Change in absolute FVC (FVCabs)
- Follow-up
- 12 months
Methodological detailssingle-centre, non-randomized, Treatment at the discretion of the primary clinician
- Single-centre
- Non-randomized
- Treatment at the discretion of the primary clinician
Main finding
As reported in the abstract
FVCabs
- MMF/AZA: FVCabs unchanged, 2.4 l (95% CI 2.0, 3.2 l) vs 2.3 l (95% CI 2.0, 2.8 l)
- Tacrolimus (TAC): FVCabs improved, 2.5 l (95% CI 2.0, 3.0 l) vs 1.9 l (95% CI 1.0, 2.6 l)
Observational data: associations, not effects.
Further findings
Transplant-free survival · 12 months
| Outcome | TAC | MMF/AZA |
|---|---|---|
| Resolution of supplemental oxygen requirement · 12 months | 4/5 | — not stated in the abstract |
— not stated in the abstract
Resolution of supplemental oxygen requirement · 12 months
- All MMF/AZA patients remained on supplemental oxygen
Original publication
Tacrolimus as first-line therapy in a US cohort of idiopathic inflammatory myopathies related interstitial lung disease. Rheumatology (Oxford). Published 3 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →